Q&A: Edinburgh BioQuarter Official Talks About Center's Commercialization Efforts | GenomeWeb

Simon Best emerged as one of the UK’s top life-sciences entrepreneurs more than a decade ago as CEO of Roslin Biomed, a Roslin Institute commercial offshoot that held intellectual property rights to the technologies behind Dolly the sheep, the first mammal cloned from an adult cell in 1997.

Two years later, Best merged the company with Geron to form Geron BioMed, then became a chief executive for various companies. Today, he is an entrepreneur-in-residence at venture-capital firm TVM Capital.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.